{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:55:27Z","timestamp":1776873327101,"version":"3.51.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00467-016-3355-z","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T12:03:23Z","timestamp":1456747403000},"page":"1029-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome"],"prefix":"10.1007","volume":"31","author":[{"given":"Song\u00fcl","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z. Birsin","family":"\u00d6z\u00e7akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysel","family":"Taktak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Kiremit\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Ensari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"Din\u00e7aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fato\u015f","family":"Yal\u00e7\u0131nkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"3355_CR1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579\u2013591","journal-title":"Nat Rev Cancer"},{"key":"3355_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2302\/kjm.61.47","volume":"61","author":"Y Kubota","year":"2012","unstructured":"Kubota Y (2012) Tumour angiogenesis and anti-angiogenic therapy. Keio J Med 61:47\u201356","journal-title":"Keio J Med"},{"key":"3355_CR3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129\u20131136","journal-title":"N Engl J Med"},{"key":"3355_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","volume":"50","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203\u2013218","journal-title":"Am J Kidney Dis"},{"key":"3355_CR5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"3355_CR6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389","journal-title":"J Am Soc Nephrol"},{"key":"3355_CR7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","volume":"30","author":"M Ollero","year":"2015","unstructured":"Ollero M, Sahali D (2015) Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant 30:1449\u20131455","journal-title":"Nephrol Dial Transplant"},{"key":"3355_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","volume":"62","author":"R Roskoski Jr","year":"2007","unstructured":"Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62:179\u2013213","journal-title":"Crit Rev Oncol Hematol"},{"key":"3355_CR9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1152\/ajprenal.00275.2009","volume":"297","author":"J M\u00fcller-Deile","year":"2009","unstructured":"M\u00fcller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M (2009) The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 297:1656\u20131667","journal-title":"Am J Physiol Renal Physiol"},{"key":"3355_CR10","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129\u20133140","journal-title":"Mol Cancer Ther"},{"key":"3355_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041552-200401000-00002","volume":"13","author":"V Eramina","year":"2004","unstructured":"Eramina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9\u201315","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3355_CR12","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1002\/cncr.28343","volume":"119","author":"J Fangusaro","year":"2013","unstructured":"Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M (2013) Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a pediatric brain tumor consortium study (PBTC-022). Cancer 119:4180\u20134187","journal-title":"Cancer"},{"key":"3355_CR13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439\u2013448","journal-title":"Eur J Cancer"},{"key":"3355_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, P\u00e9choux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D (2014) Expression patterns of RelA and cmip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457\u2013470","journal-title":"Kidney Int"},{"key":"3355_CR15","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","volume":"26","author":"NS Azad","year":"2008","unstructured":"Azad NS, Psoadas EM, Kwitkoski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kods HL, Premkumar A, Cao L, Mecnally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709\u20133714","journal-title":"J Clin Oncol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3355-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-016-3355-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3355-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:07:17Z","timestamp":1559092037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-016-3355-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1007\/s00467-016-3355-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}